作者:Anthony Knight、Jennifer L. Hemmings、Ian Winfield、Michele Leuenberger、Eugenia Frattini、Bruno G. Frenguelli、Simon J. Dowell、Martin Lochner、Graham Ladds
DOI:10.1021/acs.jmedchem.5b01402
日期:2016.2.11
A series of N6-bicyclic and N6-(2-hydroxy)cyclopentyl derivatives of adenosine were synthesized as novel A1R agonists and their A1R/A2R selectivity assessed using a simple yeast screening platform. We observed that the most selective, high potency ligands were achieved through N6-adamantyl substitution in combination with 5′-N-ethylcarboxamido or 5′-hydroxymethyl groups. In addition, we determined
合成了一系列腺苷的N 6-双环和N 6-(2-羟基)环戊基衍生物,作为新型A 1 R激动剂,并使用简单的酵母筛选平台评估了其A 1 R / A 2 R选择性。我们观察到,通过与5'- N-乙基羧酰胺基或5'-羟甲基基团结合的N 6-金刚烷基取代获得了最具选择性,最高效的配体。此外,我们确定5'-(2-氟)硫代苯基衍生物尽管显示出与A 1 R的相互作用,但均未产生信号响应。一些选定的化合物也已在A 1上进行了测试哺乳动物细胞中的R和A 3 R揭示其中四个完全是A 1 R选择性激动剂。通过使用计算机同源性建模和配体对接,我们可以深入了解其识别和激活A 1 R的机制。我们认为,鉴于腺苷受体亚型的组织分布广泛,但信号传递曲线却相反,这些化合物可能具有治疗作用。潜在的。